Early research (Phase 1)UnknownNCT05270772What this trial is testingCAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALLWho this might be right forCD19+ Relapse/Refractory B-ALL Chinese PLA General Hospital 9
Testing effectiveness (Phase 2)Looking for participantsNCT04484012What this trial is testingModified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaWho this might be right forRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma City of Hope Medical Center 36
Testing effectiveness (Phase 2)UnknownNCT05429905What this trial is testingDual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaWho this might be right forLymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in Children+2 more KK Women's and Children's Hospital 48
Not applicableUnknownNCT05066022What this trial is testingAccess the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapsed and/or Refractory Multiple Myeloma The First Affiliated Hospital of Soochow University 24
Testing effectiveness (Phase 2)UnknownNCT03896854What this trial is testingCART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Who this might be right forAcute Myeloid Leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 15
Testing effectiveness (Phase 2)Looking for participantsNCT07473154What this trial is testingControlling Hyperactive Immunity With Long-lived LymphocytesWho this might be right forDiffuse Cutaneous Systemic SclerosisRheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+1 more Quell Therapeutics Limited 16
Early research (Phase 1)Ended earlyNCT03203369What this trial is testingStudy to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCNWho this might be right forBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Cellectis S.A. 1
Early research (Phase 1)Looking for participantsNCT06176690What this trial is testingConstitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasWho this might be right forCD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more Baylor College of Medicine 90
Early research (Phase 1)Active Not RecruitingNCT04903080What this trial is testingHER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With EpendymomaWho this might be right forEpendymoma Children's Oncology Group 50
Not applicableLooking for participantsNCT06850285What this trial is testingCD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory LymphomaWho this might be right forLymphoma, B-Cell Shanxi Bethune Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT07551349What this trial is testingDual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaWho this might be right forAdvanced or Metastatic Clear Cell Renal Cell Carcinoma Beijing Biotech 36
Early research (Phase 1)Study completedNCT03019055What this trial is testingStudy of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellWho this might be right forLymphoma, Non-HodgkinLymphoma, B-CellChronic Lymphocytic Leukemia+1 more Medical College of Wisconsin 26
Large-scale testing (Phase 3)Ended earlyNCT05664217What this trial is testingNKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaWho this might be right forNon-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma Nektar Therapeutics 15
Testing effectiveness (Phase 2)UnknownNCT04089215What this trial is testingCD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins LymphomaWho this might be right forLymphoma, Non-HodgkinDiffuse Large B Cell LymphomaFollicular Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. 82
Early research (Phase 1)Active Not RecruitingNCT05057715What this trial is testingHuCART-meso + VCN-01 in Pancreatic and Ovarian CancerWho this might be right forPancreatic CancerSerous Ovarian Cancer University of Pennsylvania 13
Early research (Phase 1)Study completedNCT03958656What this trial is testingT-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaWho this might be right forMyeloma-MultipleMyeloma, Plasma-Cell National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Ended earlyNCT05172596What this trial is testingPHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Novartis Pharmaceuticals 146
Large-scale testing (Phase 3)Looking for participantsNCT06904729What this trial is testingChimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in ChildrenWho this might be right forLupus Nephritis Guangzhou Women and Children's Medical Center 50
Very early researchUnknownNCT06379451What this trial is testingAn Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple MyelomaWho this might be right forMultiple Myeloma Changzhou No.2 People's Hospital 9
Not applicableLooking for participantsNCT06389305What this trial is testingCIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell DysfunctionWho this might be right forB-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid Leukemia Beijing GoBroad Hospital 213